Safety & Regulatory Context
Safety and official sources
GLP Week Coach is an educational routine support companion. It does not replace your clinician, prescription label, local medical guidance or emergency services. These links are provided for general safety context only.
GLP Week Coach is built with safety as a core principle. The links below point to official resources from medicines regulators, national health authorities, and technology providers. GLP Week Coach does not interpret or summarise these resources — they are provided as independent reference points only.
These sources are not used to provide diagnosis, treatment, dose guidance, medication guidance, symptom interpretation or emergency support. GLP Week Coach is not affiliated with, endorsed by, reviewed by or approved by any of these organisations. All links open external websites.
United States
- U.S. Food & Drug Administration (FDA) — Drug Safety The U.S. regulatory authority for food, drugs, medical devices and biologics. Official source for drug approvals, safety communications, GLP-1 medicine safety advisories and prescribing information.
- MedlinePlus / U.S. National Library of Medicine — Semaglutide Trusted consumer medicine information from the world's largest medical library, part of the National Institutes of Health. Includes semaglutide drug information pages.
- NIDDK / NIH — Prescription Medicines for Overweight and Obesity The National Institute of Diabetes and Digestive and Kidney Diseases provides public information on prescription weight-management medicines, including GLP-1 receptor agonists.
United Kingdom
- NHS — Semaglutide injection (Ozempic) The UK's publicly funded healthcare system. Authoritative source for health information, clinical guidelines and patient-facing medicine information including semaglutide.
- GOV.UK / MHRA — Medicines and Healthcare products Regulatory Agency The UK government agency responsible for ensuring medicines and medical devices are effective and acceptably safe. Issues drug safety updates, Yellow Card reports, and GLP-1 medicine guidance.
Canada
- Health Canada The Canadian federal department responsible for helping Canadians maintain and improve their health. Provides drug product database, product monographs, and safety advisories including for GLP-1 medicines.
European Union
- EMA — Wegovy European Public Assessment Report The European Medicines Agency evaluates and supervises medicinal products in the EU. Provides European Public Assessment Reports and safety information for authorised medicines including Wegovy and Ozempic.
- BfArM — Federal Institute for Drugs and Medical Devices (Germany) The German federal authority responsible for authorisation of medicines and medical devices, safety assessments, and regulatory pharmacovigilance.
- Danish Medicines Agency (Lægemiddelstyrelsen) Denmark's national medicines authority, responsible for authorisation, monitoring and safety of medicines including GLP-1 products.
- AIFA — Italian Medicines Agency (Agenzia Italiana del Farmaco) Italy's national medicines regulatory authority, responsible for drug authorisation, pharmacovigilance, and medicines information for GLP-1 products in Italy.
Australia
- TGA — Therapeutic Goods Administration Australia's regulatory authority for therapeutic goods including medicines and medical devices. Provides product information, safety updates and the Australian Register of Therapeutic Goods.
Japan
- PMDA — Pharmaceuticals and Medical Devices Agency (Japan) Japan's national medicines regulatory agency, providing review reports, approved medicines information, and safety data for pharmaceutical products including GLP-1 medicines approved in Japan.
Brazil
- ANVISA — Brazilian Health Regulatory Agency Brazil's national health surveillance agency, responsible for authorisation and monitoring of pharmaceutical products, including GLP-1 medicines authorised in Brazil.
China
- NMPA — National Medical Products Administration (China) China's national medicines regulatory authority, responsible for regulation of drugs, medical devices, and cosmetics, including GLP-1 products authorised in China.
South Korea
- MFDS — Ministry of Food and Drug Safety (South Korea) South Korea's national medicines and food safety regulatory authority, responsible for the approval, monitoring and safety of pharmaceutical products including GLP-1 medicines.
Apple Health & Privacy
- Apple Privacy Apple's privacy information, including how Apple Health data is handled on-device and what is shared with apps. GLP Week Coach requests optional read-only access to body weight, step count and active energy only.
- Apple HealthKit Developer Documentation Apple's technical documentation for the HealthKit framework, including data access categories, privacy requirements, and on-device data handling. GLP Week Coach accesses body weight, step count and active energy categories only.
- Apple Health — Managing app access on iPhone Instructions for reviewing and revoking app access to Apple Health data. You can disconnect GLP Week Coach at any time through iOS Settings › Privacy & Security › Health.
- Apple App Store Review Guidelines Apple's App Review Guidelines govern what apps may and may not do. GLP Week Coach is designed in compliance with these guidelines, including requirements for health, medical, and wellness applications.
Links to external resources are provided for general educational context only. GLP Week Coach is not affiliated with, endorsed by, reviewed by or approved by any of the organisations listed above. Always follow the guidance of your prescribing clinician for any medical or health decision.